NEW YORK, December 9, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting AstraZeneca PLC (NYSE: AZN), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Health Net, Inc. (NYSE: HNT), Volcano Corporation (NASDAQ: VOLC) and Portola Pharmaceuticals, Inc. (NASDAQ: PTLA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
AstraZeneca PLC Research Report
On December 3, 2013, AstraZeneca PLC (AstraZeneca) announced a ruling by the US District Court for the Southern District of New York which ordered Apotex Corp., Apotex, Inc and Torpharm, Inc. (Apotex) to pay AstraZeneca approximately $76 million in damages. This Company informed that the ruling is a result of Apotex's infringing sales of generic omeprazole between 2004 and 2007. AstraZeneca stated that this follows a previous ruling in 2007 that found two Prilosec (omeprazole) formulation patents valid and infringed by Apotex. The Company stated that it welcomes the court's ruling and mentioned that these damages will not impact core earnings or AstraZeneca's full-year 2013 financial guidance. The Full Research Report on AstraZeneca PLC - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Salix Pharmaceuticals Ltd. Research Report
On December 3, 2013, Salix Pharmaceuticals Ltd. (Salix) announced the commencement of a cash tender offer by its indirect wholly owned subsidiary, Willow Acquisition Sub Corporation (Purchaser), to purchase all of the issued and outstanding shares of common stock, par value $0.0001 per share, of Santarus, Inc. (Santarus) at a purchase price of $32.00 per share, net to the seller in cash, without interest and subject to any required withholding taxes. The Company said that the tender offer is being made pursuant to an Offer to Purchase, dated December 3, 2013, and in connection with the previously announced definitive merger agreement, dated November 7, 2013, among Salix, Salix Pharmaceuticals, Inc., a wholly owned subsidiary of Salix (Intermediary), Purchaser and Santarus. According to Salix, the tender offer is scheduled to expire at 12:00 Midnight, New York City time, at the end of the day on December 31, 2013, unless extended. The Full Research Report on Salix Pharmaceuticals Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Health Net, Inc. Research Report
On November 29, 2013, Health Net Federal Services, LLC, a wholly owned subsidiary of Health Net, Inc. (Health Net) announced its annual Celebration of Children event at the Community Center on Fort Myer, to be hosted in conjunction with United Service Organizations of Metropolitan Washington (USO-Metro). According to the Company, more than 150 children from military bases across the DC Metro area are expected to participate in the event on December 7, 2013. Children will enjoy breakfast with Santa and Mrs. Claus, games, face painting and karaoke in a winter wonderland ballroom. Health Net also stated that its employees will take part in the event dressed up as elves and popular cartoon characters, volunteering with the festivities and donating toys for the children. The Full Research Report on Health Net, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Volcano Corporation Research Report
On December 2, 2013, Volcano Corporation (Volcano) announced that its Board of Directors has authorized a $200 million share repurchase program. The Company stated that it intends to fund the share repurchases with cash on hand. As part of the program, Volcano will enter into a $100 million Accelerated Share Repurchase (ASR) with J.P. Morgan Securities LLC (JPMorgan), as agent for JPMorgan Chase Bank, National Association, London Branch, pursuant to which, the Company will pay $100 million to JPMorgan and will receive from JPMorgan an initial delivery of 3.6 million shares of Volcano's common stock. The final number of shares to be repurchased by Volcano under the agreement will be determined at the completion of the ASR program and at settlement, the Company may receive additional shares of common stock from JPMorgan or, under certain circumstances, may be required to deliver shares of common stock or remit a settlement amount in cash, at the Company's option, to JPMorgan. The Full Research Report on Volcano Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Portola Pharmaceuticals, Inc. Research Report
On December 3, 2013, Portola Pharmaceuticals, Inc. (Portola) announced two upcoming data presentations at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held in New Orleans from December 7, 2013 to December 10, 2013. The Company informed that new data from a Phase 2 proof-of-concept study of andexanet alfa (PRT4445*), Portola's investigational Factor Xa inhibitor antidote, in healthy volunteers who received the Factor Xa inhibitor XARELTO® (rivaroxaban) will be presented in a poster session. In addition, in vitro data on PRT2070, Portola's oral, dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor, will also be presented in a poster session. Further, the Company stated that it will webcast an investor briefing during the ASH Annual Meeting. The Full Research Report on Portola Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner